Theracryf Plc

LSE (GBp): Theracryf Plc (TCF)

Last Price

0.25

Today's Change

+0.01 (4.16%)

Day's Change

0.25 - 0.25

Trading Volume

122,499

Overview

Market Cap

Shares Outstanding

Avg Volume

Avg Price (50 Days)

Avg Price (200 Days)

PE Ratio

EPS

Earnings Announcement

Previous Close

Open

Day's Range

Year Range

Trading Volume

Price Change Highlight

1 Day Change

5 Day Change

1 Month Change

3 Month Change

6 Month Change

Ytd Change

1 Year Change

3 Year Change

5 Year Change

10 Year Change

Max Change

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioral brain disorders. The company's lead product is SFX-01 that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase I clinical trials for the treatment of neurodevelopmental disorders and glioblastoma, as well as in preclinical stage for the treatment of rhabdomyosarcoma. In addition, it engages in the development of orexin 1 antagonist, which is in late preclinical stage targeting addiction and anxiety; and atypical dopamine transporter inhibitor (DAT), which is in late preclinical stage targeting fatigue and narcolepsy. The company was formerly known as Evgen Pharma plc and changed its name to Theracryf Plc in April 2024. Theracryf Plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.

Discussions
Be the first to like this. Showing 0 of 0 comments

{uid}

{comment}

Just now

Post a Comment